NASDAQ:AMPH - Amphastar Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$16.00 -0.56 (-3.38 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$16.56
Today's Range$15.98 - $16.59
52-Week Range$14.40 - $20.45
Volume458,100 shs
Average Volume196,441 shs
Market Capitalization$773.33 million
P/E Ratio42.11
Dividend YieldN/A
Beta1.42

About Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals logoAmphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Receive AMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AMPH
CUSIPN/A
Phone909-980-9484

Debt

Debt-to-Equity Ratio0.12
Current Ratio2.40
Quick Ratio1.53

Price-To-Earnings

Trailing P/E Ratio42.11
Forward P/E Ratio53.33
P/E Growth2.48

Sales & Book Value

Annual Sales$240.18 million
Price / Sales3.11
Cash Flow$0.7055 per share
Price / Cash22.68
Book Value$7.02 per share
Price / Book2.28

Profitability

EPS (Most Recent Fiscal Year)$0.38
Net Income$4.50 million
Net Margins-1.50%
Return on Equity3.39%
Return on Assets2.52%

Miscellaneous

Employees1,644
Outstanding Shares46,610,000

Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

How will Amphastar Pharmaceuticals' stock buyback program work?

Amphastar Pharmaceuticals declared that its Board of Directors has authorized a stock buyback plan on Thursday, August 10th 2017, which authorizes the company to repurchase $20,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals (NASDAQ:AMPH) announced its quarterly earnings results on Wednesday, May, 9th. The company reported ($0.05) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.08 by $0.13. The firm earned $58.40 million during the quarter, compared to the consensus estimate of $60.75 million. Amphastar Pharmaceuticals had a positive return on equity of 3.39% and a negative net margin of 1.50%. The business's revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.09 earnings per share. View Amphastar Pharmaceuticals' Earnings History.

What price target have analysts set for AMPH?

6 brokers have issued 12-month price objectives for Amphastar Pharmaceuticals' stock. Their forecasts range from $18.00 to $26.00. On average, they expect Amphastar Pharmaceuticals' stock price to reach $21.20 in the next twelve months. View Analyst Ratings for Amphastar Pharmaceuticals.

Who are some of Amphastar Pharmaceuticals' key competitors?

Who are Amphastar Pharmaceuticals' key executives?

Amphastar Pharmaceuticals' management team includes the folowing people:
  • Dr. Ziping Luo Ph.D., Chairman of The Board, Chief Scientist and Chief Operating Officer (Age 68)
  • Dr. Yongfeng Zhang Ph.D., Chief Exec. Officer, Chief Science Officer and Director (Age 71)
  • Mr. Jason B. Shandell, Pres & Director (Age 44)
  • Mr. William J. Peters, CFO, Treasurer & Sr. VP of Fin. (Age 50)
  • Mr. Rong Zhou, Exec. VP of Production Center (Age 59)

Has Amphastar Pharmaceuticals been receiving favorable news coverage?

News stories about AMPH stock have trended positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a news impact score of 0.36 on Accern's scale. They also gave news stories about the company an impact score of 47.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.59%), Dimensional Fund Advisors LP (3.62%), Rothschild Asset Management Inc. (0.68%), JPMorgan Chase & Co. (0.63%), Principal Financial Group Inc. (0.59%) and Principal Financial Group Inc. (0.59%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters. View Institutional Ownership Trends for Amphastar Pharmaceuticals.

Which major investors are selling Amphastar Pharmaceuticals stock?

AMPH stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., BlackRock Inc., Citigroup Inc., Point72 Asset Management L.P., Fisher Asset Management LLC, Russell Investments Group Ltd. and Rothschild Asset Management Inc.. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Diane G Gerst, Floyd F Petersen, Jason B Shandell, Michael A Zasloff, Richard K Prins, Stephen B Shohet and William J Peters. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Which major investors are buying Amphastar Pharmaceuticals stock?

AMPH stock was bought by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Mackay Shields LLC, Dimensional Fund Advisors LP, Matarin Capital Management LLC, Citadel Advisors LLC, Campbell & CO Investment Adviser LLC, A.R.T. Advisors LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Amphastar Pharmaceuticals.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $16.00.

How big of a company is Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals has a market capitalization of $773.33 million and generates $240.18 million in revenue each year. The company earns $4.50 million in net income (profit) each year or $0.38 on an earnings per share basis. Amphastar Pharmaceuticals employs 1,644 workers across the globe.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]


MarketBeat Community Rating for Amphastar Pharmaceuticals (AMPH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  359
MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Amphastar Pharmaceuticals in the last 12 months. Their average twelve-month price target is $21.20, suggesting that the stock has a possible upside of 32.50%. The high price target for AMPH is $26.00 and the low price target for AMPH is $18.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.67
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.20$21.20$20.60$20.3333
Price Target Upside: 32.50% upside8.66% upside8.88% upside6.46% upside

Amphastar Pharmaceuticals (NASDAQ:AMPH) Consensus Price Target History

Price Target History for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ:AMPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/21/2018Wells Fargo & CoReiterated RatingBuyMediumView Rating Details
3/13/2018BMO Capital MarketsReiterated RatingMarket Perform ➝ Market Perform$17.00 ➝ $19.00HighView Rating Details
3/13/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $24.00HighView Rating Details
1/30/2018Piper Jaffray CompaniesReiterated RatingBuy$26.00MediumView Rating Details
11/9/2017Raymond JamesDowngradeOutperform ➝ Market Perform$18.00N/AView Rating Details
10/29/2017Jefferies GroupSet Price TargetBuy$19.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Amphastar Pharmaceuticals (NASDAQ:AMPH) Earnings History and Estimates Chart

Earnings by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ:AMPH) Earnings Estimates

2018 EPS Consensus Estimate: $0.74
2019 EPS Consensus Estimate: $1.17
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.11$0.11$0.11
Q2 20181$0.11$0.11$0.11
Q3 20182$0.13$0.22$0.18
Q4 20182$0.31$0.38$0.35
Q1 20191$0.27$0.27$0.27
Q2 20191$0.29$0.29$0.29
Q3 20191$0.31$0.31$0.31
Q4 20191$0.30$0.30$0.30

Amphastar Pharmaceuticals (NASDAQ AMPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q1 2018$0.08($0.05)$60.75 million$58.40 millionViewN/AView Earnings Details
3/12/2018Q4 2017$0.07$0.10$60.62 million$60.40 millionViewListenView Earnings Details
11/8/2017Q3 2017$0.02$0.07$57.23 million$57.90 millionViewN/AView Earnings Details
8/9/2017Q2 2017$0.06$0.11$63.40 million$65.20 millionViewListenView Earnings Details
5/8/2017Q1 2017$0.06$0.03$63.74 million$56.67 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.01)$0.01$55.78 million$63.54 millionViewN/AView Earnings Details
11/8/2016Q3$0.03$0.14$65.12 million$64.20 millionViewListenView Earnings Details
8/8/2016Q2$0.01$0.23$62.10 million$68.00 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)$0.12$62.00 million$59.40 millionViewN/AView Earnings Details
3/14/2016Q415($0.04)$0.19$64.48 million$76.90 millionViewN/AView Earnings Details
11/12/2015Q315($0.20)($0.01)$19.49 million$63.90 millionViewListenView Earnings Details
8/12/2015Q215($0.11)($0.09)$19.49 million$53.85 millionViewListenView Earnings Details
5/13/2015Q115($0.17)($0.01)$45.87 million$56.89 millionViewListenView Earnings Details
3/24/2015Q414($0.06)($0.03)$54.90 million$55.90 millionViewN/AView Earnings Details
11/12/2014Q314($0.11)($0.11)$45.89 million$59.70 millionViewN/AView Earnings Details
8/12/2014Q2 2014($0.11)$0.02$44.23 million$49.00 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Amphastar Pharmaceuticals (NASDAQ:AMPH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Amphastar Pharmaceuticals (NASDAQ AMPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 31.50%
Institutional Ownership Percentage: 44.67%
Insider Trading History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ AMPH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/15/2018Jack Y ZhangCEOBuy25,000$16.08$402,000.002,065,619View SEC Filing  
3/20/2018Jason B ShandellInsiderSell20,000$19.43$388,600.00251,372View SEC Filing  
3/15/2018Richard K PrinsDirectorSell16,598$19.90$330,300.2045,442View SEC Filing  
3/14/2018Jason B ShandellInsiderSell700$20.45$14,315.00View SEC Filing  
3/13/2018William J PetersCFOSell19,801$20.10$398,000.10View SEC Filing  
1/26/2018Jason B. ShandellInsiderSell18,627$19.42$361,736.34View SEC Filing  
1/25/2018Jason B. ShandellGeneral CounselSell8,661$19.26$166,810.86View SEC Filing  
12/19/2017Diane G GerstEVPSell523$19.48$10,188.0430,164View SEC Filing  
12/14/2017Stephen B ShohetDirectorSell7,866$18.87$148,431.4231,982View SEC Filing  
12/12/2017Diane G GerstEVPSell523$18.96$9,916.0830,687View SEC Filing  
12/7/2017Stephen B ShohetDirectorSell7,862$18.34$144,189.0831,978View SEC Filing  
12/1/2017William J. PetersCFOSell6,226$19.67$122,465.42View SEC Filing  
11/30/2017Stephen B ShohetDirectorSell7,862$19.25$151,343.5031,978View SEC Filing  
11/28/2017Diane G GerstEVPSell523$18.15$9,492.4531,210View SEC Filing  
11/22/2017Stephen B ShohetDirectorSell7,862$18.94$148,906.2831,978View SEC Filing  
11/21/2017Diane G GerstEVPSell523$18.81$9,837.6331,733View SEC Filing  
11/16/2017Stephen B ShohetDirectorSell7,862$18.04$141,830.4831,978View SEC Filing  
11/15/2017Diane G GerstEVPSell523$17.77$9,293.7132,256View SEC Filing  
11/9/2017Stephen B ShohetDirectorSell7,862$18.55$145,840.1031,978View SEC Filing  
11/7/2017Diane G GerstEVPSell523$17.93$9,377.3932,779View SEC Filing  
11/2/2017Stephen B ShohetDirectorSell7,862$18.37$144,424.94View SEC Filing  
10/26/2017Stephen B ShohetDirectorSell7,862$18.39$144,582.1831,978View SEC Filing  
10/24/2017Diane G GerstEVPSell523$18.29$9,565.6733,302View SEC Filing  
10/19/2017Stephen B ShohetDirectorSell7,862$18.34$144,189.0831,978View SEC Filing  
10/17/2017Diane G GerstEVPSell523$18.48$9,665.0433,825View SEC Filing  
10/13/2017William J PetersCFOSell3,026$18.56$56,162.56View SEC Filing  
10/12/2017Stephen B ShohetDirectorSell7,862$18.73$147,255.26View SEC Filing  
10/5/2017Diane G GerstEVPSell8,444$18.87$159,338.28View SEC Filing  
10/4/2017Floyd F PetersenDirectorSell39,312$18.59$730,810.08View SEC Filing  
10/2/2017Michael A ZasloffDirectorSell63,624$18.18$1,156,684.32101,879View SEC Filing  
8/15/2017Richard K PrinsDirectorSell10,000$14.81$148,100.0033,844View SEC Filing  
8/14/2017Richard K PrinsDirectorSell5,000$14.80$74,000.0033,844View SEC Filing  
6/9/2017Richard K PrinsDirectorSell10,000$17.07$170,700.0028,844View SEC Filing  
6/1/2017Michael A ZasloffDirectorSell15,000$17.01$255,150.0047,411View SEC Filing  
5/31/2017Jason B ShandellDirectorSell11,482$16.92$194,275.44241,342View SEC Filing  
5/11/2017Richard K PrinsDirectorSell7,500$15.43$115,725.0030,500View SEC Filing  
1/3/2017Floyd F PetersenDirectorSell400$18.61$7,444.0058,717View SEC Filing  
12/15/2016Diane G GerstEVPSell2,940$20.51$60,299.4026,195View SEC Filing  
12/5/2016Rong ZhouEVPSell61$20.70$1,262.7036,991View SEC Filing  
12/1/2016Floyd F PetersenDirectorSell400$20.26$8,104.0059,117View SEC Filing  
11/28/2016Jason B ShandellInsiderSell26,335$20.48$539,340.80205,004View SEC Filing  
11/15/2016Howard LeeDirectorSell37,994$20.65$784,576.10134,527View SEC Filing  
10/3/2016Floyd F PetersenDirectorSell400$18.75$7,500.0059,917View SEC Filing  
9/26/2016Jason B ShandellInsiderSell56,996$19.50$1,111,422.00259,957View SEC Filing  
9/20/2016Jack Y ZhangCEOSell444,199$21.03$9,341,504.971,295,685View SEC Filing  
9/8/2016Floyd F PetersenDirectorSell3,000$19.05$57,150.0060,317View SEC Filing  
9/1/2016Howard LeeDirectorSell10,381$18.78$194,955.18125View SEC Filing  
8/22/2016Jason B ShandellGeneral CounselSell10,000$19.95$199,500.00212,961View SEC Filing  
8/19/2016Diane G GerstEVPSell24,046$19.28$463,606.8839,031View SEC Filing  
8/18/2016Richard K PrinsDirectorSell3,086$19.62$60,547.3226,000View SEC Filing  
8/17/2016Jason B ShandellInsiderSell5,987$18.86$112,914.82202,961View SEC Filing  
8/16/2016Stephen B ShohetDirectorSell48,375$18.24$882,360.0028,653View SEC Filing  
8/15/2016Michael A ZasloffDirectorSell48,375$18.15$878,006.2542,792View SEC Filing  
8/12/2016William J PetersCFOSell1,027$18.19$18,681.1363,625View SEC Filing  
8/11/2016Jason B ShandellPresidentSell5,636$18.01$101,504.36208,948View SEC Filing  
8/11/2016Richard K PrinsDirectorSell13,993$18.03$252,293.7931,681View SEC Filing  
7/18/2016William J PetersCFOSell2,297$17.76$40,794.7264,652View SEC Filing  
6/15/2016Rong ZhouEVPSell1,551$15.85$24,583.3537,137View SEC Filing  
6/13/2016Richard K PrinsDirectorSell7,500$15.94$119,550.0029,086View SEC Filing  
6/9/2016Jason B ShandellPresidentSell9,904$16.43$162,722.72216,610View SEC Filing  
6/2/2016William J PetersCFOSell2,297$16.00$36,752.0066,949View SEC Filing  
5/25/2016Jason B ShandellPresidentSell1,074$15.60$16,754.40226,514View SEC Filing  
5/18/2016Diane G GerstEVPSell1,427$13.97$19,935.1928,649View SEC Filing  
5/17/2016Richard K PrinsDirectorSell3,200$13.56$43,392.0023,000View SEC Filing  
4/19/2016Diane G GerstEVPSell21,244$12.89$273,835.1639,713View SEC Filing  
4/18/2016Diane G GerstEVPSell15,637$12.83$200,622.7139,713View SEC Filing  
3/17/2016Richard K PrinsDirectorSell2,400$11.25$27,000.0026,200View SEC Filing  
12/17/2015Stephen B. ShohetDirectorSell30,770$14.19$436,626.3012,186View SEC Filing  
12/16/2015Howard LeeDirectorSell38,462$14.34$551,545.08109,901View SEC Filing  
12/16/2015Rong ZhouEVPSell772$14.29$11,031.8825,460View SEC Filing  
12/11/2015Jack Y ZhangCEOSell63,300$14.25$902,025.00920,117View SEC Filing  
12/8/2015Jack Y ZhangCEOSell68,117$14.71$1,002,001.07920,117View SEC Filing  
12/3/2015Jack Y ZhangCEOSell38,583$15.45$596,107.35920,117View SEC Filing  
8/18/2015Richard K PrinsDirectorSell9,100$14.66$133,406.00View SEC Filing  
8/17/2015Richard K. PrinsDirectorSell5,400$14.70$79,380.0035,722View SEC Filing  
7/17/2015Michael A ZasloffDirectorSell7,692$17.41$133,917.72View SEC Filing  
6/17/2015Rong ZhouEVPSell1,000$16.48$16,480.00View SEC Filing  
6/15/2015Jack Y ZhangCEOSell45,382$16.29$739,272.78View SEC Filing  
6/12/2015Jack Y ZhangCEOSell160,495$16.23$2,604,833.85View SEC Filing  
6/9/2015Jack Y ZhangCEOSell193,758$16.43$3,183,443.94View SEC Filing  
5/22/2015Richard K PrinsDirectorSell29,452$14.77$435,006.04View SEC Filing  
5/19/2015Richard K PrinsDirectorSell3,000$14.94$44,820.00View SEC Filing  
4/9/2015Marilyn J PurchaseVPSell28,000$15.79$442,120.00View SEC Filing  
4/8/2015Diane G GerstSVPSell10,000$15.79$157,900.00View SEC Filing  
8/25/2014Howard LeeDirectorBuy6,000$10.84$65,040.00View SEC Filing  
8/19/2014Michael A ZasloffDirectorBuy3,500$10.00$35,000.00View SEC Filing  
8/18/2014Richard K PrinsDirectorBuy4,000$10.02$40,080.00View SEC Filing  
8/15/2014Floyd F PetersenDirectorBuy3,200$10.35$33,120.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amphastar Pharmaceuticals (NASDAQ AMPH) News Headlines

Source:
DateHeadline
Amphastar Pharmaceuticals (AMPH) Receives Consensus Rating of "Hold" from AnalystsAmphastar Pharmaceuticals (AMPH) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - May 24 at 3:23 PM
Zacks: Analysts Expect Amphastar Pharmaceuticals (AMPH) Will Announce Quarterly Sales of $64.08 MillionZacks: Analysts Expect Amphastar Pharmaceuticals (AMPH) Will Announce Quarterly Sales of $64.08 Million
www.americanbankingnews.com - May 21 at 2:10 AM
Amphastar Pharmaceuticals (AMPH) Expected to Post Earnings of $0.08 Per ShareAmphastar Pharmaceuticals (AMPH) Expected to Post Earnings of $0.08 Per Share
www.americanbankingnews.com - May 19 at 9:16 PM
Amphastar Pharmaceuticals (AMPH) Upgraded by BidaskClub to "Buy"Amphastar Pharmaceuticals (AMPH) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - May 19 at 1:00 PM
Falling Earnings Estimates Signal Weakness Ahead for Amphastar (AMPH)Falling Earnings Estimates Signal Weakness Ahead for Amphastar (AMPH)
finance.yahoo.com - May 18 at 10:41 AM
Insider Buying: Amphastar Pharmaceuticals (AMPH) CEO Buys 25,000 Shares of StockInsider Buying: Amphastar Pharmaceuticals (AMPH) CEO Buys 25,000 Shares of Stock
www.americanbankingnews.com - May 17 at 7:55 PM
How Should You Think About Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) Risks?How Should You Think About Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) Risks?
finance.yahoo.com - May 16 at 4:17 PM
Amphastar Pharmaceuticals (AMPH) Downgraded to "Strong Sell" at Zacks Investment ResearchAmphastar Pharmaceuticals (AMPH) Downgraded to "Strong Sell" at Zacks Investment Research
www.americanbankingnews.com - May 15 at 4:27 PM
Benzingas Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference UnderwayBenzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway
www.msn.com - May 15 at 10:20 AM
Amphastar Pharmaceuticals (AMPH) Q1 2018 Results - Earnings Call TranscriptAmphastar Pharmaceuticals' (AMPH) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 14 at 4:16 PM
FDA OKs Amphastars generic calcium chloride injectionFDA OKs Amphastar's generic calcium chloride injection
seekingalpha.com - May 14 at 10:36 AM
BRIEF-Amphastar Pharmaceuticals Receives FDA Approval For Calcium Chloride InjectionBRIEF-Amphastar Pharmaceuticals Receives FDA Approval For Calcium Chloride Injection
www.reuters.com - May 14 at 10:36 AM
Edited Transcript of AMPH earnings conference call or presentation 9-May-18 9:00pm GMTEdited Transcript of AMPH earnings conference call or presentation 9-May-18 9:00pm GMT
finance.yahoo.com - May 14 at 10:36 AM
Amphastar Pharmaceuticals Receives FDA Approval for Calcium Chloride InjectionAmphastar Pharmaceuticals Receives FDA Approval for Calcium Chloride Injection
finance.yahoo.com - May 14 at 10:36 AM
Q4 2018 EPS Estimates for Amphastar Pharmaceuticals Increased by Jefferies Group (AMPH)Q4 2018 EPS Estimates for Amphastar Pharmaceuticals Increased by Jefferies Group (AMPH)
www.americanbankingnews.com - May 14 at 4:05 AM
Amphastar Pharmaceuticals to Post Q3 2018 Earnings of $0.22 Per Share, Piper Jaffray Forecasts (AMPH)Amphastar Pharmaceuticals to Post Q3 2018 Earnings of $0.22 Per Share, Piper Jaffray Forecasts (AMPH)
www.americanbankingnews.com - May 14 at 3:13 AM
Amphastar Pharmaceuticals (AMPH) Downgraded to Sell at ValuEngineAmphastar Pharmaceuticals (AMPH) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - May 11 at 11:13 AM
Amphastar Pharmaceuticals (AMPH) Posts Quarterly  Earnings Results, Misses Estimates By $0.13 EPSAmphastar Pharmaceuticals (AMPH) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS
www.americanbankingnews.com - May 10 at 6:12 PM
BRIEF-Amphastar Pharmaceuticals Q1 GAAP Loss Per Share $0.16BRIEF-Amphastar Pharmaceuticals Q1 GAAP Loss Per Share $0.16
www.reuters.com - May 10 at 9:55 AM
Amphastar: 1Q Earnings SnapshotAmphastar: 1Q Earnings Snapshot
www.cnbc.com - May 10 at 9:55 AM
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2018Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2018
finance.yahoo.com - May 9 at 4:19 PM
Zacks: Analysts Anticipate Amphastar Pharmaceuticals (AMPH) Will Announce Quarterly Sales of $60.17 MillionZacks: Analysts Anticipate Amphastar Pharmaceuticals (AMPH) Will Announce Quarterly Sales of $60.17 Million
www.americanbankingnews.com - May 4 at 3:40 AM
Amphastar Pharmaceuticals (AMPH) Upgraded at ValuEngineAmphastar Pharmaceuticals (AMPH) Upgraded at ValuEngine
www.americanbankingnews.com - May 4 at 12:54 AM
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2018Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2018
finance.yahoo.com - May 3 at 4:14 PM
$0.09 Earnings Per Share Expected for Amphastar Pharmaceuticals (AMPH) This Quarter$0.09 Earnings Per Share Expected for Amphastar Pharmaceuticals (AMPH) This Quarter
www.americanbankingnews.com - May 2 at 11:25 AM
Amphastar Pharmaceuticals (AMPH) Given Average Rating of "Hold" by BrokeragesAmphastar Pharmaceuticals (AMPH) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 29 at 3:15 PM
Is Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) Balance Sheet Strong Enough To Weather A Storm?Is Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - April 28 at 10:06 AM
Amphastar Pharmaceuticals Inc (AMPH) Expected to Post Quarterly Sales of $63.15 MillionAmphastar Pharmaceuticals Inc (AMPH) Expected to Post Quarterly Sales of $63.15 Million
www.americanbankingnews.com - April 17 at 4:00 AM
Amphastar Pharmaceuticals Inc (AMPH) Expected to Announce Earnings of $0.09 Per ShareAmphastar Pharmaceuticals Inc (AMPH) Expected to Announce Earnings of $0.09 Per Share
www.americanbankingnews.com - April 15 at 11:15 AM
Amphastar Pharmaceuticals Inc (AMPH) Receives Consensus Recommendation of "Hold" from AnalystsAmphastar Pharmaceuticals Inc (AMPH) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 4 at 5:52 PM
What Is Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) Share Price Doing?What Is Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) Share Price Doing?
finance.yahoo.com - April 4 at 5:17 PM
Amphastar Pharmaceuticals (AMPH) Downgraded by Raymond James Financial to "Market Perform"Amphastar Pharmaceuticals (AMPH) Downgraded by Raymond James Financial to "Market Perform"
www.americanbankingnews.com - March 31 at 6:34 PM
Amphastar Pharmaceuticals Inc (AMPH) Expected to Announce Quarterly Sales of $63.15 MillionAmphastar Pharmaceuticals Inc (AMPH) Expected to Announce Quarterly Sales of $63.15 Million
www.americanbankingnews.com - March 31 at 3:00 AM
Amphastar Pharmaceuticals (AMPH) Downgraded by BidaskClubAmphastar Pharmaceuticals (AMPH) Downgraded by BidaskClub
www.americanbankingnews.com - March 30 at 9:17 AM
Amphastar Pharmaceuticals (AMPH) Presents At Needham and Company 17th Annual Healthcare Conference - SlideshowAmphastar Pharmaceuticals (AMPH) Presents At Needham and Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:16 PM
 Analysts Expect Amphastar Pharmaceuticals Inc (AMPH) to Post $0.09 EPS Analysts Expect Amphastar Pharmaceuticals Inc (AMPH) to Post $0.09 EPS
www.americanbankingnews.com - March 29 at 1:52 PM
Is Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) A Sell At Its Current PE Ratio?Is Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) A Sell At Its Current PE Ratio?
finance.yahoo.com - March 28 at 9:57 AM
Amphastar Pharmaceuticals to Present at the Needhams 17th Annual Healthcare ConferenceAmphastar Pharmaceuticals to Present at the Needham's 17th Annual Healthcare Conference
globenewswire.com - March 26 at 4:09 PM
Amphastar Pharmaceuticals (AMPH) Earns Buy Rating from Piper JaffrayAmphastar Pharmaceuticals (AMPH) Earns Buy Rating from Piper Jaffray
www.americanbankingnews.com - March 26 at 1:26 PM
Amphastar Pharmaceuticals to Present at the Needham’s 17th Annual Healthcare ConferenceAmphastar Pharmaceuticals to Present at the Needham’s 17th Annual Healthcare Conference
finance.yahoo.com - March 26 at 10:11 AM
Amphastar Pharma (AMPH) Reports Favorable Final Judgement in Patent Litigation Against Momenta Pharmaceuticals Inc. and Sandoz Inc.Amphastar Pharma (AMPH) Reports Favorable Final Judgement in Patent Litigation Against Momenta Pharmaceuticals Inc. and Sandoz Inc.
www.streetinsider.com - March 23 at 9:39 AM
Amphastar Pharmaceuticals (AMPH) Buy Rating Reaffirmed at Wells FargoAmphastar Pharmaceuticals' (AMPH) Buy Rating Reaffirmed at Wells Fargo
www.americanbankingnews.com - March 22 at 10:54 PM
Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc. - GlobeNewswire (press release)Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc. - GlobeNewswire (press release)
globenewswire.com - March 22 at 4:11 PM
Head to Head Comparison: Pernix Therapeutics (PTX) vs. Amphastar Pharmaceuticals (AMPH)Head to Head Comparison: Pernix Therapeutics (PTX) vs. Amphastar Pharmaceuticals (AMPH)
www.americanbankingnews.com - March 21 at 1:20 PM
Amphastar Pharma (AMPH) Reports Favorable Final Judgement in Patent Litigation Against Momenta Pharmaceuticals ... - StreetInsider.comAmphastar Pharma (AMPH) Reports Favorable Final Judgement in Patent Litigation Against Momenta Pharmaceuticals ... - StreetInsider.com
www.streetinsider.com - March 21 at 10:55 AM
Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc. - NasdaqAmphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc. - Nasdaq
www.nasdaq.com - March 21 at 10:55 AM
Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc.Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc.
finance.yahoo.com - March 21 at 10:54 AM
Jason B. Shandell Sells 20,000 Shares of Amphastar Pharmaceuticals Inc (AMPH) StockJason B. Shandell Sells 20,000 Shares of Amphastar Pharmaceuticals Inc (AMPH) Stock
www.americanbankingnews.com - March 20 at 10:14 PM
Amphastar Pharmaceuticals (AMPH) Raised to Hold at BidaskClubAmphastar Pharmaceuticals (AMPH) Raised to Hold at BidaskClub
www.americanbankingnews.com - March 18 at 7:10 PM
Richard K. Prins Sells 16,598 Shares of Amphastar Pharmaceuticals Inc (AMPH) StockRichard K. Prins Sells 16,598 Shares of Amphastar Pharmaceuticals Inc (AMPH) Stock
www.americanbankingnews.com - March 16 at 7:52 PM

SEC Filings

Amphastar Pharmaceuticals (NASDAQ:AMPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amphastar Pharmaceuticals (NASDAQ:AMPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amphastar Pharmaceuticals (NASDAQ AMPH) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.